UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH

Equities researchers at LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma (NASDAQ:URGN) in a research note issued to investors on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $31.00 price target on the stock. LADENBURG THALM/SH SH’s target price points to a potential upside of 189.45% from the stock’s previous close.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Tuesday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $39.20.

UroGen Pharma Trading Down 1.0 %

URGN stock opened at $10.71 on Wednesday. The firm has a fifty day moving average price of $10.75 and a 200 day moving average price of $12.21. UroGen Pharma has a fifty-two week low of $9.78 and a fifty-two week high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a market cap of $251.15 million, a PE ratio of -3.40 and a beta of 1.08.

Insiders Place Their Bets

In other news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

Institutional Trading of UroGen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Toronto Dominion Bank bought a new stake in shares of UroGen Pharma during the fourth quarter worth $18,628,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of UroGen Pharma by 2.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock worth $14,667,000 after purchasing an additional 36,084 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of UroGen Pharma by 307.5% during the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after purchasing an additional 1,230,000 shares during the last quarter. Stonepine Capital Management LLC raised its holdings in shares of UroGen Pharma by 15.7% in the fourth quarter. Stonepine Capital Management LLC now owns 324,324 shares of the company’s stock valued at $3,454,000 after acquiring an additional 43,979 shares in the last quarter. Finally, RTW Investments LP raised its holdings in shares of UroGen Pharma by 1.3% in the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after acquiring an additional 47,447 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.